Name Ethinylestradiol + Lynestrenol
Classes Hormonal Agent
Hormone
Contraceptive
Hormone Combination
Diseases Follicle Maturation
Gonadotropin Release
Gyeconological Disorder
Menstrual Bleeding
Prevention of Pregnancy

Ethinylestradiol + Lynestrenol

Ethinylestradiol + Lynestrenol is a combination of two hormonal contraceptives, which belongs to the class of estrogen-progestin combination. Ethinylestradiol is a synthetic estrogen and lynestrenol is a progestin. The contraceptive effect of ethinylestradiol + lynestrenol results from the inhibition of ovulation through the suppression of follicular maturation and the prevention of LH (Luteinizing hormone) surge, as well as the thickening of cervical mucus, which inhibits sperm penetration.

 

Ethinylestradiol + Lynestrenol is indicated for the prevention of pregnancy in women of reproductive age who choose to use hormonal contraception.

 

The dosage and administration of Ethinylestradiol + Lynestrenol should be individualized based on the patient's medical history and current health status. The usual dose is one tablet daily for 21 days, followed by a 7-day pill-free period. The tablets should be taken at the same time each day. A new pack should be started on the eighth day, regardless of whether or not menstrual bleeding has stopped. Women who have not used hormonal contraceptives in the past month should start on the first day of their menstrual cycle.

 

The following adverse reactions have been reported with the use of Ethinylestradiol + Lynestrenol:

  • Nausea
  • Headache
  • Breast tenderness
  • Irregular vaginal bleeding or spotting
  • Weight changes
  • Mood changes
  • Decreased libido
  • Vaginal discharge
  • Skin rash or hives
  • Fluid retention/ edema
  • High blood pressure
  • Blood clots

 

  • Women using Ethinylestradiol + Lynestrenol should not smoke. Smoking increases the risk of serious cardiovascular events, such as heart attack, stroke, and blood clots.
  • Women with a history of cardiovascular disease, hypertension, or thromboembolic disorders should be monitored closely while using Ethinylestradiol + Lynestrenol.
  • Ethinylestradiol + Lynestrenol should not be used by women who are pregnant or breastfeeding.
  • Women who are experiencing severe or prolonged headaches, visual disturbances, chest pain, shortness of breath, or leg swelling should discontinue use of Ethinylestradiol + Lynestrenol and seek medical attention.
  • Women with a history of liver disease or gallbladder disease should be monitored closely while using Ethinylestradiol + Lynestrenol.
  • Women who are taking medications that can interact with Ethinylestradiol + Lynestrenol, such as certain antibiotics and anticonvulsants, should use alternative forms of contraception.
  • Ethinylestradiol + Lynestrenol does not protect against sexually transmitted infections.

 

Contraindication

Contraindicated in patients hypersensitive to any component of the formulation.

Ethinylestradiol + Lynestrenol is contraindicated in the following health conditions-

  • High risk of arterial or venous thrombotic diseases. 
  • Breast cancer or other estrogen- or progestin-sensitive cancer.
  • Undiagnosed abnormal uterine bleeding. 
  • Liver tumors
  • acute viral hepatitis 
  • decompensated cirrhosis